期刊文献+

替吉奥胶囊处方优选 被引量:3

Study on Formulation and Preparation of Tegafur,Gimeracil and Oteracil Capsules
在线阅读 下载PDF
导出
摘要 目的筛选替吉奥胶囊的最佳处方组成。方法以辅料中的乳糖、十二烷基硫酸钠、硬脂酸镁作为考察因素,每个因素取3个水平,用L9(34)正交表安排试验,以替吉奥胶囊的溶出度为主要考察指标,以颗粒流动性和外观为参照指标,进行正交试验。结果辅料中影响胶囊溶出度的主要因素是十二烷基硫酸钠(P<0.05),最佳处方组成为乳糖60g,十二烷基硫酸钠4g,硬脂酸镁1.5g。结论采用该处方及工艺制得的替吉奥胶囊溶出度较高,而且产品质量稳定,制备工艺简单可行,适合工业化大生产。 Objective To screen the optimum formulation technique of tegafur, gimeracil and oteracil capsules. Methods The 1.9(34) orthogonal table and three factors (dissolution, the grain liquidity and appearance as reference factors) were used to select the best formulation by taking lactose, with sodium lauryl sulfate and magnesium stearate as the three main factors,and three levels were adopted for each factors. Results The experimental results indicated sodium lauryl sulfate was the chief factor of influencing dissolution of tegafur, gimeracil and oteracil capsules (P〈 0.05).Lactose and magnesium stearate had no statistic significance. The optimum formulation was composed of tegafur, gimeracil and oteracil capsules,lactose 60 g,sodium lauryl sulfate 4 g, magnesium stearate 1.5 g. Conclusion The optimum formulation and preparing technique are reliable. The quality of tegafur, gimeracil and oteracil capsules accord with China pharmacopoeia standard. Because the preparing technique is simple and feasible,it is suitable for industrialized production.
出处 《中国药业》 CAS 2006年第11期44-45,共2页 China Pharmaceuticals
关键词 替吉奥胶囊 处方 正交试验设计 溶出度 tegafur, gimeracil and oteracil capsules formulation orthogonal experiment design dissolution
  • 相关文献

参考文献2

二级参考文献6

共引文献3

同被引文献15

  • 1张晗.治疗胃癌的复方新药S-1的研究进展[J].国外医学(药学分册),2005,32(5):304-307. 被引量:8
  • 2Sato A, Ito T, Tomita T, et al. Chemotherapy of gastric cancer-a review of clinical trials in Japan [J]. Gan To Kagaku Ryoho, 2002, 29 (9): 1522.
  • 3Tanaka F, Fukuse T, Wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents [J]. Curt Pharm Biotechnol, 2000, 1 (2): 137.
  • 4Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity of fluoropyrimidines by metabolic and target enzyme activities in gastric cancer [J]. Gastric Cancer, 2003, 6 (Suppl 1): 71.
  • 5Yoshisue K, Hironaga K, Yamaguchi S, et al. Reduction of 5- fluorouracil gastroiontestinal toxicity resulting from the prtection of thymidylate synthase in gastrointestinal tissue by repeated simultaneous administration of potassium oxonate in rats [J]. Cancer ChemotherPharmacol, 2000, 46 (1): 51.
  • 6Yoshisue K, Masuda H, Matsushima E, et al. Tissue distribution and biotransformation of potassium oxonate after oral administration of a novel antitumor agent(drug combination of tegafur, 5- chloro-2,4-dihydroxypyridine, and potassium oxonate) to rats[J]. Drug Metab Dispos, 2000,28 (10) : 1162.
  • 7刘江华,戚苏明,陈国俊,陆宏国,苏苗.替吉奥胶囊临床研究进展[J].中国现代医生,2008,46(30):62-63. 被引量:32
  • 8孙莉.HPLC法测定替吉奥片中3种成分的含量[J].中国药事,2008,22(11):984-986. 被引量:10
  • 9张金淑.替吉奥治疗晚期胃癌30例[J].中国药业,2011,20(7):73-73. 被引量:13
  • 10陈玉超.晚期胃癌病机探析[J].长春中医药大学学报,2011,27(6):951-953. 被引量:16

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部